Danaher(US:DHR) Jing Ji Guan Cha Wang·2026-02-13 16:46Group 1: Financial Performance - The company plans to release its official financial report for Q4 and the full year of 2025 in late February 2026, with management indicating that Q4 performance will exceed expectations and core revenue growth will approach the upper end of guidance [2] - For 2026, the company has set clear targets, including a core revenue growth of 3% to 6% year-over-year, an adjusted operating profit margin expansion of over 100 basis points, and an adjusted earnings per share (EPS) target of high single-digit growth [3] Group 2: Industry Conditions - The growth momentum for 2026 will partially depend on the continued recovery of the life sciences market, increased demand for bioprocessing equipment, and a rebound in the Chinese diagnostics market, which will directly impact the company's performance [4] Group 3: Strategic Initiatives - The company noted that the merger and acquisition environment is improving and emphasized maintaining discipline by focusing on acquisition targets that align with its core strategic areas in biotechnology, life sciences, and diagnostics [5] Group 4: Business Developments - In Q4 2025, the company's biotechnology business performed well, with sales increasing by approximately 9% year-over-year. The diagnostics business, particularly the Cepheid product line (especially respiratory testing), showed strong sales and received FDA approval for gastrointestinal pathogen testing, indicating promising future product pipeline advancements [6]